SCHEMBL3532445

SCHEMBL3532445

Cc1nc2cc(-c3cnc(N)c4c(-c5ccc(NC(=O)Nc6cccc(Cl)c6)cc5)csc34)ccc2s1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.68
AURKB Q96GD4 11/20 0.68
PLK4 O00444 6/20 0.64
LCK P06239 6/20 0.64
CSF1R P07333 6/20 0.64
LYN P07948 6/20 0.64
KIT P10721 6/20 0.64
FGFR1 P11362 6/20 0.64
BLK P51451 6/20 0.64
NEK2 P51955 6/20 0.64
STK3 Q13188 6/20 0.64
MARK2 Q7KZI7 6/20 0.64
AURKA O14965 5/20 0.64
ROCK2 O75116 5/20 0.64
ROCK1 Q13464 5/20 0.64
NTRK2 Q16620 5/20 0.64
ABL1 P00519 5/20 0.64
FYN P06241 5/20 0.64
LIMK1 P53667 5/20 0.64
PRKD2 Q9BZL6 5/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3531566 0.91 KDR (0.75) KDRAURKBPLK4LCKCSF1R
SCHEMBL3529022 0.86 KDR (0.64) KDRAURKBPLK4LCKCSF1R
SCHEMBL3532221 0.85 KDR (0.78) KDRAURKBPLK4LCKCSF1R
SCHEMBL3526606 0.85 FGFR1 (0.67) KDRAURKBPLK4LCKCSF1R
SCHEMBL3529859 0.84 KDR (0.85) KDRAURKBPLK4LCKCSF1R
SCHEMBL3530472 0.84 KDR (0.80) KDRAURKBPLK4LCKCSF1R
SCHEMBL3525059 0.83 KDR (0.80) KDRAURKBPLK4LCKCSF1R
SCHEMBL3526620 0.82 KDR (0.73) KDRAURKBPLK4LCKCSF1R
SCHEMBL3526155 0.82 KDR (0.73) KDRAURKBPLK4LCKCSF1R
SCHEMBL3528523 0.82 KDR (0.81) KDRAURKBPLK4LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 EP disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885PLK4 442/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885PLK4 442/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885PLK4 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.